Protein kinases and pseudokinases are a superfamily of proteins and account for about 2% of human genes. This family of proteins mediates the activation of key signaling pathways involved in many biological processes. Hence, mutations affecting these groups of proteins are known to be associated with human tumor onset and progression. So far, more than 70 small molecule inhibitors have been approved by the FDA, poising kinases as the second most important targets of precision therapy. However, development of drug resistance is still a major hurdle to overcome. Therefore, understanding the fundamental molecular mechanisms by which kinases and pseudokinases modulate cancer development will severely impact the design of more effective inhibitors.
In this Special Issue of Cancers, we invite authors to submit contributions that provide novel findings in the field of kinases and pseudokinases. We will cover recent advances on the basic mechanisms by which kinases/pseudokinases modulate cancer development and mechanisms of drug resistance or development of new therapeutic approaches. We welcome results from the basic research, preclinical, or clinical fields. Reviews that highlight new findings in the areas mentioned above are also welcome.
We look forward to receiving your contributions.
Dr. Bibiana I. Ferreira
Dr. Ana Luísa De Sousa-Coelho
For more information, click here.